Net income up 23% at Schering AG as Betaferon sales stay strong

9 November 2001

Schering AG of Germany says that net sales increased 7% to 3.58 billioneuros ($3.22 billion) for the first nine months of 2001 and net income improved 23% to 331 million euros. Operating profit, however, advanced just 4% to 494 million euros, reflecting investments in its new product launches both in the USA and Europe, the company notes.

The multiple sclerosis drug Betaferon/Betaseron (interferon beta-1b) continued to be Schering's largest-selling product, with turnover up 12% to 491 million euros for the six months. The firm notes that, in the USA, the success of Betaferon and the chronic lymphocytic leu-kemia drug Fludara (fludarabine), with sales up 22% at 100 million euros), enabled Schering to cushion the fall of Betapace (sotalol), turnover of which fell 49% to 77 million euros.

Strong start for Campath

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight